Tranosyl™ is a novel proprietary tRNA anti-sense technology platform to inhibit the growth and proliferation of cancer cells. Tranosyl has two components of selective toxicity. First, it targets over-expressed or unique cell surface proteins expressed specifically on cancerous cells. The second level of selective toxicity is achieved by targeting conserved portions of t-RNA, also known as the 28s-binding subunit of ribosomal RNA molecules (rRNA) contained therein.
Tranosyl technology involves the synthesis and delivery of complementary nucleotide strands designed to bind to the 5’ prime end of t-RNA - the site of t-RNA activation for reading messenger RNA (m-RNA) on ribosomes, a critical step in translation. Tranosyl™ also delivers biologically inactive amino acid residues, which will cause the t-RNA to be nonfunctional. This will eventually block all t-RNAs, particularly those involved in the production of "housekeeping" proteins. Interruption of housekeeping protein synthesis will lead ultimately to cell death by inducing self-directed apoptosis.